- Home
- REVB vs SNES Comparison
REVB vs SNES Comparison
Compare REVB & SNES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- SNES
- Stock Information
- Founded
- REVB 2020
- SNES 2004
- Country
- REVB United States
- SNES United States
- Employees
- REVB N/A
- SNES N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- SNES Agricultural Chemicals
- Sector
- REVB Health Care
- SNES Industrials
- Exchange
- REVB Nasdaq
- SNES Nasdaq
- Market Cap
- REVB 2.3M
- SNES 2.3M
- IPO Year
- REVB N/A
- SNES 2016
- Fundamental
- Price
- REVB $4.31
- SNES $3.03
- Analyst Decision
- REVB
- SNES Strong Buy
- Analyst Count
- REVB 0
- SNES 1
- Target Price
- REVB N/A
- SNES $10.00
- AVG Volume (30 Days)
- REVB 175.9K
- SNES 97.2K
- Earning Date
- REVB 03-21-2025
- SNES 02-28-2025
- Dividend Yield
- REVB N/A
- SNES N/A
- EPS Growth
- REVB N/A
- SNES N/A
- EPS
- REVB N/A
- SNES N/A
- Revenue
- REVB N/A
- SNES $1,651,000.00
- Revenue This Year
- REVB N/A
- SNES $76.36
- Revenue Next Year
- REVB N/A
- SNES $103.47
- P/E Ratio
- REVB N/A
- SNES N/A
- Revenue Growth
- REVB N/A
- SNES 38.16
- 52 Week Low
- REVB $3.34
- SNES $1.90
- 52 Week High
- REVB $69.44
- SNES $9.80
- Technical
- Relative Strength Index (RSI)
- REVB 40.86
- SNES 47.13
- Support Level
- REVB $3.80
- SNES $3.18
- Resistance Level
- REVB $4.54
- SNES $3.63
- Average True Range (ATR)
- REVB 0.37
- SNES 0.42
- MACD
- REVB 0.18
- SNES 0.00
- Stochastic Oscillator
- REVB 68.13
- SNES 31.26
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.